Virtual Public Meeting: Endpoint Considerations to Facilitate Drug Development for Niemann-Pick Type C (NPC)

Posted by

On January 24-25, 2022, the FDA and Duke-Margolis Center for Health Policy will host a virtual public
workshop on endpoint considerations to facilitate drug development for NPC. During this workshop,
participants will discuss clinical endpoints relevant to NPC clinical trials and innovative strategies to
support therapeutic development for patients with NPC. The workshop is open to the public and will
include representation from the patient community, the academic community, health care
providers, industry, and other federal partners.

Registration at the meeting website

Featured image: wikipedia

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.